Drugs in ATC Class D05

Up to Top Level ATC Classes

Up to D - Dermatologicals

Subclasses in ATC: D05 - ANTIPSORIATICS

D05A - ANTIPSORIATICS FOR TOPICAL USE

D05B - ANTIPSORIATICS FOR SYSTEMIC USE

Market Dynamics and Patent Landscape for ATC Class D05 – Antipsoriatics

Last updated: July 30, 2025

Introduction

The ATC (Anatomical Therapeutic Chemical) classification system, maintained by the World Health Organization (WHO), segments drugs based on their therapeutic, pharmacological, and chemical characteristics. Class D05 encompasses antipsoriatic agents, medicines designed specifically to treat psoriasis—a chronic, immune-mediated skin disorder impacting millions worldwide. Given psoriasis's significant burden and its evolving treatment landscape, understanding market dynamics alongside the patent landscape offers valuable insights for stakeholders.

This analysis explores the key drivers shaping the antipsoriatic market, recent innovations, patent trends, and strategic considerations for industry participants.

Market Overview and Drivers

Growing Prevalence of Psoriasis

Global epidemiological data estimate psoriasis affects approximately 2-3% of the population, translating into over 125 million individuals worldwide. High prevalence in North America and Europe, coupled with increasing awareness, has fueled market growth. As diagnostic precision improves, particularly with advances in dermoscopy and biopsy, the number of diagnosed cases is rising, expanding the treatment market.

Advancements in Therapeutics

Historically, topical agents like corticosteroids and vitamin D analogs formed the mainstay treatments. Recently, the segment has shifted towards biologic therapies targeting specific immune pathways (e.g., TNF-alpha inhibitors, IL-17 inhibitors). These biologics demonstrate superior efficacy and safety profiles, driving treatment paradigm shifts.

Small-molecule drugs, such as phosphodiesterase-4 (PDE4) inhibitors (e.g., apremilast), also gained prominence, offering oral administration with moderate efficacy and favorable safety profiles. The rising pipeline of innovative drugs addresses unmet needs for moderate to severe psoriasis, bolstering market growth.

Regulatory Approvals and Market Penetration

Regulatory agencies like the FDA and EMA continue to approve novel therapies, broadening treatment options. Recently, drugs like bimekizumab (an IL-17A and IL-17F inhibitor) gained marketing authorization, deepening therapeutic choices.

Market penetration varies by geographic region due to cost, healthcare infrastructure, and physician preferences. The high cost of biologics limits access in certain regions, prompting efforts to develop biosimilars and affordable small-molecule alternatives.

Patient-Reported Outcomes and Personalized Treatments

Patient-centric measures influence therapeutic choices. The rise of personalized medicine enables stratified treatments based on genetic, biomarker, and disease severity considerations, likely impacting future market segmentation and growth.

Pricing, Reimbursement, and Market Access Challenges

High drug costs, especially for biologics, challenge market expansion. Payers increasingly demand cost-effectiveness evidence, impacting drug uptake. Biosimilars promise to mitigate cost pressures, fostering competitive dynamics within the industry.

Patent Landscape Overview

Patent Trends in Antipsoriatic Drugs

Patent filings in D05 primarily focus on novel molecular entities, formulations, delivery mechanisms, and combination therapies. The landscape reflects a strategic push toward extending patent exclusivity and navigating around patent cliffs of blockbuster biologics.

Key Periods and Patent Filing Waves:

• Late 2000s to early 2010s: Major biologic patent filings, including TNF-alpha inhibitors like infliximab and adalimumab.
• Mid-2010s: Introduction of biosimilar patents and formulations enhancing drug stability and delivery.
• Recent years: Focus on small-molecule innovations such as PDE4 inhibitors, IL inhibitors, and nanotechnology-based delivery platforms.

Patents on Biologic Therapies

Biologics—monoclonal antibodies, fusion proteins—remain dominant in patent filings. Companies like AbbVie, Johnson & Johnson, and Novartis hold extensive patents covering compositions, methods of manufacturing, and indications. Patent expiry of key biologic patents, anticipated between 2024-2030, catalyzes biosimilar development.

Innovations in Small Molecules and Formulations

Patent filings emphasize novel chemical entities targeting immune pathways (e.g., IL-23 inhibitors). Formulation patents improve drug stability, topical bioavailability, and patient adherence.

Challenges in the Patent Landscape

• Patent Litigation and Extensions: Companies leverage patent thickets and pediatric exclusivity extensions to prolong market exclusivity.
• Patent Cliff Risks: Expiry of key patents threatens revenue streams, incentivizing investment in next-generation molecules and combination therapies.
• Generic and Biosimilar Competition: Entry of biosimilars after patent expiry exerts downward pressure on prices and market share.

Strategic Implications for Industry Participants

• Pipeline Diversification: Companies must innovate beyond existing biologics, emphasizing small molecules, oral agents, and targeted topical formulations.
• Global Patent Strategies: Securing patents in emerging markets mitigates revenue risk and fosters market expansion.
• Focus on Biosimilars: Preparing for imminent patent expiries necessitates acceleration in biosimilar development and regulatory pathways.
• Formulation and Delivery Innovations: Patents on novel delivery systems can create competitive moats, especially for topical and transdermal therapies.

Future Outlook

The antipsoriatic market is expected to grow at a compound annual growth rate (CAGR) of approximately 8-10% over the next five years, driven by unmet needs and innovation. The patent landscape will continue to evolve, with increasing emphasis on biosimilars, combination therapies, and personalized treatments.

Emerging therapies targeting new immune pathways, such as IL-36 and Janus kinase (JAK) inhibitors, promise to diversify the market further. Patent strategies will remain pivotal, influencing drug availability, pricing, and access.

Key Takeaways

• Market Expansion: Driven by rising prevalence, advances in biologics, and personalized therapy approaches.
• Patent Dynamics: Heavy patent filings on biologics with upcoming expirations open opportunities for biosimilars, necessitating strategic patent filings.
• Innovation Focus: Small-molecule therapies and novel formulations are critical in extending market exclusivity and addressing price sensitivities.
• Regulatory and Market Access: Cost containment and reimbursement policies significantly influence market dynamics across regions.
• Strategic Considerations: Patent portfolios, clinical pipeline progression, and formulation innovations will determine competitive positioning.

FAQs

1. How do current patent expiries affect the antipsoriatic drug market?
Patent expiries for biologics like Humira (adalimumab) are opening the door for biosimilar entrants, increasing competition and reducing prices. Companies are investing in next-generation biologics and formulations to maintain market share, while biosimilars threaten revenue from blockbuster drugs.

2. What are the key innovation areas in antipsoriatic therapeutics?
Focus areas include small-molecule oral agents (such as PDE4 and JAK inhibitors), next-generation biologics targeting IL-23 and IL-36 pathways, and advanced topical formulations with improved penetration and efficacy.

3. Which regions pose the greatest opportunities for market growth?
Emerging markets like Asia-Pacific and Latin America present significant growth potential owing to rising prevalence, expanding healthcare infrastructure, and increasing access to biologics and biosimilars.

4. How are biosimilars influencing the patent landscape?
Biosimilars challenge originator biologics post-patent expiry, fostering price competition and expanding patient access. Patent strategies now increasingly include formulations, delivery mechanisms, and manufacturing processes to protect innovations against biosimilar competition.

5. What role does personalized medicine play in future antipsoriatic therapies?
Personalized medicine enables tailored treatments based on genetic and biomarker profiles, improving efficacy and reducing adverse effects. This approach influences drug development priorities and patent strategies centered around companion diagnostics and targeted therapies.

---

Sources:
[1] WHO ATC/DDD Index, 2022.
[2] Market Research Future, 2023.
[3] European Medicines Agency, 2023.
[4] Fitch Solutions, 2023.
[5] U.S. Patent and Trademark Office Data, 2023.